SOURCEPHLEX
LIVE

Serial Number

79246041

Owner

PharmaLex GmbH

Attorney

Mark J. Liss

Filing Date

Jan 12, 2018

Add to watchlist:

No watchlists yet
View on USPTO

SOURCEPHLEX Trademark

Serial Number: 79246041 • Registration: 6039116

SOURCEPHLEX is a trademark filed by PharmaLex GmbH on January 12, 2018. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PharmaLex GmbH (10 trademarks)

Bahnstrasse 42-46

Entity Type: 99

Trademark Details

Filing Date

January 12, 2018

Registration Date

April 28, 2020

Published for Opposition

February 11, 2020

Goods & Services

Advertising services, business management for others; company administration services, namely, business administration services; providing office functions; business efficiency expert services; systemization of information into computer databases; compilation of information into computer databases; business assistance and consultancy in the context of the retailing and wholesaling of medicines; providing of outsourcing services in the field of medicine authorisation, production, sale, safety and monitoring

Public document filing assistance in the field of medicine authorization, namely, public document filing services pertaining to documents for authorizing medicines featuring documents, reports and files required by regulatory authorities; regulatory compliance consultancy in the field of pharmaceuticals

Medical and veterinary medical services; pharmacy advice, namely, provision of pharmaceutical advice for pharmaceutical and medical device companies; providing information relating to the preparation and dispensing of medications

Scientific and technological services and research and design relating thereto, namely, scientific research, laboratory research in the field of pharmaceuticals; industrial analysis and research services in the field of pharmaceuticals; scientific research and development of new products for others in the field of pharmaceuticals; provision of scientific surveys, namely, medical research surveys; development of a web application for inputting and using informative texts for medicines and medical products, in particular user guides, packaging inserts, specialist information, and for providing various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; research in relation to scientific work; preparation of scientific analysis and assessments; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing; pharmaceutical products development; development of pharmaceutical preparations and medicines; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical drug development services; medical laboratory services; information technology services for the pharmaceutical and healthcare industries, namely, information technology consulting services; scientific assessment of the efficiency of medicines; services for assessing the efficiency of pharmaceuticals, namely, pharmaceutical product evaluation; scientific analysis and evaluation of product design; scientific analysis and evaluation of product development; quality control testing; materials testing and evaluation; product safety testing; quality control services, namely, testing, analysis and evaluation of the goods of others to determine conformity with certification standards; quality testing of products to determine conformity with certification standards; assistance and consultancy in the nature of pharmaceutical research in the field of medicine safety and monitoring; pharmaceutical drug development consultancy in the field of medicine safety

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 28, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 15, 2024 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 18, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 26, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 6, 2020 FICS
FINAL DISPOSITION PROCESSED
Sep 1, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 28, 2020 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 22, 2020 OPNX
NEW REPRESENTATIVE AT IB RECEIVED
May 21, 2020 NREP
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2020 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 22, 2020 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 22, 2020 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2020 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Feb 7, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 22, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 22, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 22, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 16, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 16, 2019 GNFN
FINAL REFUSAL E-MAILED
Jul 16, 2019 GNFR
FINAL REFUSAL WRITTEN
Jul 16, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 17, 2019 CRFA
ASSIGNED TO LIE
Jun 14, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2019 TROA
REFUSAL PROCESSED BY IB
Dec 28, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 12, 2018 RFCS
REFUSAL PROCESSED BY MPU
Dec 11, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Nov 30, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 29, 2018 RFCR
NON-FINAL ACTION WRITTEN
Nov 28, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 26, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 26, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 22, 2018 REPR